Lucentis® Prefilled Syringe for Retinal Diseases

Lucentis® Prefilled Syringe contains ranibizumab for intravitreal injection by an eye care professional. It treats certain retinal diseases that can cause vision loss. CanadianInsulin ships from Canada to the US, offering Canadian pricing with US delivery from Canada for patients and clinics comparing cost, including those paying without insurance.

What Lucentis® Is and How It Works

At CanadianInsulin, orders are filled by licensed Canadian pharmacies after we confirm a valid prescription with your clinic.

Lucentis® (ranibizumab) is a vascular endothelial growth factor A (VEGF-A) inhibitor. It binds VEGF-A to reduce abnormal blood vessel growth and leakage in the retina and macula. The prefilled, single-use syringe is designed for one intravitreal dose administered under aseptic conditions by a retina specialist or ophthalmologist. This anti-VEGF therapy is widely used for neovascular eye diseases, including wet age-related macular degeneration, macular edema, diabetic eye disease, and myopic choroidal neovascularization.

The prefilled format streamlines preparation and provides a consistent, ready-to-inject dose. Clinical use focuses on stabilizing vision and reducing retinal fluid measured by clinical exam and imaging.

Who Lucentis® Is For

Lucentis is indicated for adults with the following conditions diagnosed by an eye care professional:

• Neovascular (wet) age-related macular degeneration
• Macular edema following retinal vein occlusion (branch or central)
• Diabetic macular edema
• Diabetic retinopathy
• Myopic choroidal neovascularization

Learn more about wet AMD in our condition guide for Wet AMD.

Lucentis should not be used in patients with ocular or periocular infection, active intraocular inflammation, or a known hypersensitivity to ranibizumab or any component of the formulation. Caution is advised in pregnancy and during breastfeeding; discuss potential risks and benefits with a clinician. Patients with a history of stroke or myocardial infarction should be assessed individually due to the small risk of arterial thromboembolic events reported with intravitreal anti-VEGF therapy.

Dosage and Usage

Lucentis dosing is set by the treating ophthalmologist based on indication and clinical response. Standard label-directed schedules include:

• Wet AMD: 0.5 mg intravitreal injection once monthly (approximately every 28 days).
• Retinal vein occlusion-related macular edema: 0.5 mg once monthly.
• Diabetic macular edema and diabetic retinopathy: 0.3 mg once monthly.
• Myopic choroidal neovascularization: 0.5 mg initially; additional monthly injections if needed based on clinical findings.

Injections are performed in an appropriate clinical setting with sterile technique and local anesthesia. Intraocular pressure and the injection site are monitored according to clinical standards. Scheduling and any interval adjustments are determined by the treating clinician based on disease activity and vision goals.

For a general overview of approved uses and dosing, see our guide: Lucentis Uses.

Strengths and Forms

Lucentis Prefilled Syringe presentations commonly include:

• 0.5 mg in 0.05 mL prefilled syringe (often described as 10 mg/mL)
• 0.3 mg in 0.05 mL prefilled syringe

Availability can vary by market and supplier. Ranibizumab is also supplied in single-use vials in some settings; your clinic may prefer a specific presentation. The ranibizumab prefilled syringe options allow clinicians to select 0.5 mg or 0.3 mg doses consistent with labeled indications.

Keywords some patients use when comparing products include Ranibizumab Prefilled Syringe 0.5 mg, Ranibizumab Prefilled Syringe 0.3 mg, and Lucentis 10 mg/mL Prefilled Syringe.

Missed Dose and Timing

If a scheduled injection appointment is missed, contact the clinic to reschedule as soon as possible. The clinician will determine timing for the next dose. Do not attempt to self-administer or adjust dosing without medical direction.

Storage and Travel Basics

Store Lucentis Prefilled Syringe refrigerated at 2°C to 8°C (36°F to 46°F). Keep in the original carton to protect from light. Do not freeze. Do not shake. Keep out of reach of children. The clinic prepares the syringe immediately before use.

For transport to the clinic, keep the sealed carton in an insulated container with frozen gel packs, separated by a barrier to prevent freezing. Avoid direct sunlight, car trunks, or heater vents. During hotter months or longer trips, plan for reliable cold-chain handling. CanadianInsulin supports prompt, express, cold-chain shipping to maintain proper temperature during transit.

Pen Handling and Sharps Disposal

Lucentis Prefilled Syringe is not a patient-operated pen. It is a sterile, single-use syringe handled by trained eye care professionals. The syringe is used once and discarded per medical sharps procedures by the clinic. Never reuse and never attempt to recap or alter the syringe.

Benefits

Lucentis helps reduce retinal and macular fluid, which may stabilize or improve vision in indicated conditions. The prefilled syringe offers:

• Consistent, ready-to-use dosing with fewer preparation steps in clinic
• Single-use design to support sterility and dosing accuracy
• Therapeutic targeting of VEGF-A to control leakage and neovascularization

Outcomes vary by condition and individual response. Vision monitoring and imaging guide ongoing treatment decisions.

Side Effects and Safety

Common ocular side effects include:

• Conjunctival hemorrhage or redness
• Eye pain or irritation
• Increased intraocular pressure shortly after injection
• Floaters or vitreous detachment symptoms
• Blurred vision or discomfort at the injection site

Serious risks, while uncommon, include endophthalmitis, retinal detachment or tear, significant increases in intraocular pressure, and arterial thromboembolic events such as stroke or myocardial infarction. Hypersensitivity reactions, including severe allergic responses, can occur. Lucentis should not be given in the presence of active ocular or periocular infection or significant intraocular inflammation. Any new severe eye pain, worsening vision, light sensitivity, or purulent discharge requires urgent clinical assessment.

Drug Interactions and Cautions

Systemic drug interactions with intravitreal ranibizumab are not prominent. Important cautions include:

• Concurrent intravitreal procedures or ocular surgery: timing is managed by the treating ophthalmologist.
• Antithrombotic therapy: ocular surface bleeding can be more noticeable; clinical decisions balance risks and benefits.
• History of stroke or heart attack: assess potential risk of arterial thromboembolic events.
• Pregnancy and breastfeeding: discuss potential risks; data are limited.
• Active infection or inflammation: defer injection until resolved.

Always share a complete medical and ocular history with the treating clinic.

What to Expect Over Time

Treatment often starts with monthly injections. Many patients show reduced retinal fluid on imaging and stabilization of vision during the first months. Ongoing follow-up is required, and the clinic determines whether to continue monthly dosing or adjust intervals based on disease activity and visual outcomes. Some conditions require long-term maintenance to sustain results.

Compare With Alternatives

Approved anti-VEGF alternatives include aflibercept and brolucizumab. Many clinics also use Lucentis in vial form depending on workflow and coverage. Two commonly considered options are Eylea® and Beovu®. For background reading, patients and caregivers sometimes review comparisons such as Eylea vs Lucentis and Macugen vs Lucentis before discussing options with the retina specialist.

Pricing and Access

Buy Lucentis Prefilled Syringe online from Canada with US shipping. Many compare Lucentis Prefilled Syringe price, cost, and cash price between US and Canadian sources. CanadianInsulin lists current pricing with Canadian pricing and ships to the US. This helps patients, clinics, and self-pay caregivers plan for ongoing therapy.

Order Lucentis Prefilled Syringe with encrypted checkout and clinic prescription verification. To see current Lucentis Prefilled Syringe cost and potential savings, visit the product page. Some patients search terms like Lucentis Prefilled Syringe online, Lucentis Prefilled Syringe from Canada, Lucentis Prefilled Syringe ships to US, and Ranibizumab Prefilled Syringe price when budgeting for monthly care. If looking for seasonal offers, check our Promotions page.

For those evaluating vial-based purchasing with a clinic, this article may help: Lucentis Vial Savings.

Availability and Substitutions

Supply can vary by strength and presentation. If a particular Lucentis Prefilled Syringe strength is unavailable, a prescriber may recommend a clinically appropriate alternative or a different presentation. Substitution decisions are always made by the treating clinician to match the indication and dosing needs.

Patient Suitability and Cost Saving Tips

Lucentis is intended for adults diagnosed with the listed retinal conditions. It is not self-administered. Patients with active eye infection or intraocular inflammation should postpone treatment until cleared. Those with recent cardiovascular events require individualized risk assessment.

• Ask whether scheduling multiple upcoming injections is appropriate so planning and budgeting are smoother.
• Consider aligning orders with clinic appointments to reduce extra trips and maintain cold-chain integrity.
• Set calendar reminders for refills and follow-up imaging visits.
• Discuss 0.3 mg versus 0.5 mg dosing where applicable; dosing depends on the specific indication.
• Compare Ranibizumab 0.5 mg Injection and Ranibizumab 0.3 mg Injection options if the clinic requests a specific dose.

Questions to Ask Your Clinician

• Which dose is recommended for this diagnosis (0.3 mg or 0.5 mg), and why?
• How many monthly injections are typically needed before re-evaluating the plan?
• What signs after injection require same-day contact with the clinic?
• How will intraocular pressure be monitored during treatment?
• Is switching between prefilled syringe and vial ever appropriate in this case?
• Are there concerns related to recent cardiovascular events or current anticoagulant therapy?
• What is the plan if disease activity persists despite regular treatment?

Authoritative Sources

For official prescribing and product details, see:

• Genentech Lucentis Prescribing Information
• FDA Label for Lucentis
• Health Canada Drug Product Database

Start your order with US delivery from Canada and maintain cold-chain shipping for clinic day.